Overview

Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

Status:
Completed
Trial end date:
2019-02-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerance of a new intravenous diagnostic agent, SeeMore or EVP 1001-1, in patients with Cardiovascular Disease (MEMRI scan). The initial phase of this study, NCT01989195 enrolling a total of 6 patients, has been closed. This second phase adds 10 patients in a safety cohort and 60 additional patients for a total of 70 patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Stanford University
Collaborator:
General Electric
Treatments:
Manganese